The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 3, 2013, Pages 201-223

  Anisimov, Vladimir N ^a   Bartke, Andrzej ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Antidiabetic biguanides; Cancer prevention; Growth hormone; IGF 1

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADIPONECTIN; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; CHROMIUM PICOLINATE; CLOFIBRATE; CLOMIFENE CITRATE; ESTRADIOL; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN; MELATONIN; METFORMIN; PENTOSIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHENFORMIN; PROLACTIN; RAPAMYCIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SULFONYLUREA; TAMOXIFEN CITRATE; THYROTROPIN; TRANSCRIPTION FACTOR PIT 1; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG;

AGING; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST TUMOR; CALORIC RESTRICTION; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; COLON CANCER; COLON POLYP; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; EVENING DOSAGE; GENE INACTIVATION; GROWTH HORMONE DEFICIENCY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LACTIC ACIDOSIS; LIFE EXTENSION; LIVER CELL CARCINOMA; LIVER TUMOR; LONGEVITY; LUNG TUMOR; MALIGNANT FIBROUS HISTIOCYTOMA; MUTANT; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TUMOR; UTERINE CERVIX CARCINOMA;

AGING; ANTIDIABETIC BIGUANIDES; CANCER PREVENTION; GROWTH HORMONE; IGF-1;

AGING; ANIMALS; CALORIC RESTRICTION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GROWTH HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LONGEVITY; MALE; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84881661464     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.01.005     Document Type: Review

References (236)

1. Johnson T.E. Increased life-span of age-1 mutants in Caenorhabditis elegans and lower Gompertz rate of aging. Science 1990, 249:908-912.
2. Kenyon C., Chang J., Gensch E., Rudner A., Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature 1993, 366:461-464.
3. Kimura K.D., Tissenbaum H.A., Liu Y., Ruvkun G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 1997, 277:942-946.
4. Tissenbaum H.A., Ruvkun G. An insulin-like signaling pathway affects both longevity and reproduction in Caenorhabditis elegans. Genetics 1998, 148:703-717.
5. Guarente L., Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 2000, 408:255-262.
6. Longo V.D., Finch C.E. Evolutionary medicine, from dwarf model systems to healthy centenarians?. Science 2003, 299:1342-1346.
7. Tatar M., Bartke A., Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003, 299:1346-1351.
8. Holzenberger M., Dupont J., Ducos B., et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003, 421:182-187.
9. Conover C.A., Bale L.K., Mader J.R., Mason M.A., Keenan K.P., Marler R.J. Longevity and age-related pathology of mice deficient in pregnancy-associated plasma protein-A. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2010, 65:590-599.
10. Blüher M., Kahn B., Kahn C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003, 299:572-574.
11. Taguchi A., Wartschow L.M., White M.F. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007, 317:369-372.
12. Selman C., Partridge L., Withers D.J. Replication of extended lifespan phenotype in mice with deletion of insulin receptor substrate 1. PLoS ONE 2011, 6(1):e16144. PMCID: 3026792.
13. Brown-Borg H.M., Borg K.E., Meliska C.J., Bartke A. Dwarf mice and the aging process. Nature 1996, 384:33.
14. Flurkey K., Papaconstantinou J., Miller R.A., Harrison D.E. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:6736-6741.
15. Coschigano K.T., Holland A.N., Riders M.E., List E.O., Flyvbjerg A., Kopchick J.J. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 2003, 144:3799-3810.
16. Bartke A. Single-gene mutations and healthy ageing in mammals. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences 2011, 366:28-34.
17. Ikeno Y., Bronson R.T., Hubbard G.B., Lee S., Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2003, 58:291-296.
18. Ikeno Y., Hubbard G.B., Lee S., et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2009, 64:522-529.
19. Vergara M., Smith-Wheelock M., Harper J.M., Sigler R., Miller RA Hormone-treated Snell dwarf mice regain fertility but remain long lived and disease resistant. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2004, 59:1244-1250.
20. Kinney B.A., Coschigano K.T., Kopchick J.J., Steger R.W., Bartke A. Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiology and Behavior 2001, 72:653-660.
21. Kinney B.A., Meliska C.J., Steger R.W., Bartke A. Evidence that Ames dwarf mice age differently from their normal siblings in behavioral and learning and memory parameters. Hormones and Behavior 2001, 39:277-284.
22. Anisimov V.N. Carcinogenesis and aging 1987, vol. 2. CRC Press, Boca Raton, FL.
23. Strong R., Miller R.A., Astle C.M., et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 2008, 7:641-650.
24. Harrison D.E., Strong R., Sharp Z.D., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
25. Spindler S.R. Caloric restriction: from soup to nuts. Ageing Research Reviews 2010, 9:324-353.
26. Anisimov V.N. Premature ageing prevention: limitations and perspectives of pharmacological interventions. Current Drugs Targets 2006, 7:1485-1503.
27. Anisimov V.N. Carcinogenesis and aging 20 years after: escaping horizon. Mechanisms of Ageing and Development 2009, 130:105-121.
28. Weindruch R., Walford R. The retardation of aging and disease by dietary restriction 1988, C. C. Thomas, Springfield, IL.
29. Masoro E.J. Caloric restriction and ageing, controversial issues. Journal of Gerontology: Biological Sciences 2006, 61A:14-19.
30. Barzilai N., Bartke A. Biological approaches to mechanistically understand the healthy life span extension achieved by calorie restriction and modulation of hormones. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2009, 64:187-191.
31. Roth G.S., Ingram D.K., Lane M.A. Calorie restriction in primates, will it work and how will we know?. Journal of the American Geriatrics Society 1999, 46:869-903.
32. Colman R.J., Anderson R.M., Johnson S.C., et al. Calorie restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
33. Mattison J.A., Roth G.S., Beasley T.M., et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012, 489:318-321.
34. Meyer T.E., Kovács S.J., Ehsani A.A., Klein S., Holloszy J.O., Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. Journal of the American College of Cardiology 2006, 47(January (2)):398-402.
35. Holloszy J.O., Fontana L. Caloric restriction in humans. Experimental Gerontology 2007, 42:709-712.
36. Willcox D.C., Willcox B.J., Todoriki H., et al. Caloric restriction and human longevity: what can we learn from the Okinawans?. Biogerontology 2006, 7:173-177.
37. Braekman B.P., Demetrius L., Vandfleteren J.R. The dietary restriction effect in C. elegans and humans: is the worm a one-millimeter human?. Biogerontology 2006, 7:127-133.
38. Goto S. Health span extension by later-life caloric or dietary restriction: a view based on rodent studies. Biogerontology 2006, 7:135-138.
39. Le Bourg E. Dietary restriction would probably not increase longevity in human being and other species able to leave unsuitable environments. Biogerontology 2006, 7:149-152.
40. Shanley D.P., Kirkwood T.B. Caloric restriction does not enhance longevity in all species and is unlikely to do so in humans. Biogerontology 2006, 7:165-168.
41. Yu B.P. Why calorie restriction would work for human longevity. Biogerontology 2006, 7:179-182.
42. Anderson R., Weindruch R. The caloric restriction paradigm: implications for healthy human aging. American Journal of Human Biology 2012, 24:101-106.
43. Anderson R., Weindruch R. Metabolic reprogramming, caloric restriction and aging. Trends in Endocrinology & Metabolism 2010, 21:134-141.
44. Tatar M., Kopelman A., Epstein D., Tu M.P., Yin C.M., Garofalo R.S. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 2001, 292:107-110.
45. Lund J., Tedesco P., Duke K., Wang J., Kim S.K., Johnson T.E. Transcriptional profile of aging in C. elegans. Current Biology 2002, 12:1566-1573.
46. Pinkston-Gosse J., Kenyon C. DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans. Nature Genetics 2007, 39:1403-1409.
47. Pinkston-Gosse J., Gaigan D., Hansen M., Kenyon C. Mutations that increase the life span of C. elegans inhibit tumor growth. Science 2006, 313:971-975.
48. Lee S.S., Kennedy S., Tolonen A.C., Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science 2003, 300:644-647.
49. Kapeller L., De Magalhaes Filho C., Dupont J., et al. Brain IGF-1 receptors control mammalian growth and life span through a neuroendocrine mechanism. PLoS Biology 2008, 6(10):e254. 10.1371/journal.pbio.0060254.
50. Selman C., Lingard S., Choudhury A.I., et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB Journal 2008, 22:807-818.
51. Sharp Z.D., Bartke A. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2005, 60:293-300.
52. Bonkowski M.S., Dominici F.P., Arum O., et al. Disruption of growth hormone receptor prevents calorie restriction from improving insulin action and longevity. PLoS ONE 2009, 4(2):e4567.
53. McCormick M.A., Tsai S.Y., Kennedy B.K. TOR and ageing: a complex pathway for a complex process. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences 2011, 366:17-27.
54. Anisimov V.N., Zabezhinski M.A., Popovich I.G., et al. Rapamycin extends maximal life span in cancer-prone mice. American Journal of Pathology 2010, 176:1092-1209.
55. Anisimov V.N., Zabezhinski M.A., Popovich I.G., et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011, 10:4230-4236.
56. Selman C., Tullet J.M., Wieser D., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
57. Salmon A.B., Murakami S., Bartke A., Kopchick J., Yasumura K., Miller R.A. Fibroblast cell lines from young adult mice of long-lived mutant strains are resistant to multiple forms of stress. American Journal of Physiology: Endocrinology and Metabolism 2005, 289:E23-E30.
58. Panici J.A., Harper J.M., Miller R.A., Bartke A., Spong A., Masternak M.M. Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. FASEB Journal 2010, 24:5073-5079.
59. Brown-Borg H.M. Longevity in mice: is stress resistance a common factor?. Age 2006, 28:145-162.
60. Sun L.Y., Bokov A.F., Richardson A., Miller R.A. Hepatic response to oxidative injury in long-lived Ames dwarf mice. FASEB Journal 2011, 25:398-408.
61. Murakami S., Johnson T.E. A genetic pathway conferring life extension and resistance to UV stress in Caenorhabditis elegans. Genetics 1996, 143:1207-1218.
62. Lithgow G.J., White T.M., Melov S., Johnson T.E. Thermotolerance and extended life-span conferred by single-gene mutations and induced by thermal stress. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7540-7544.
63. Dekker P., Maier A.B., van Heemst D., et al. Stress-induced responses of human skin fibroblasts in vitro reflect human longevity. Aging Cell 2009, 8:595-603.
64. Bokov A.F., Lindsey M.L., Khodr C., Sabia M.R., Richardson A. Long-lived Ames dwarf mice are resistant to chemical stressors. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2009, 64:819-827.
65. Aguirre V., Werner E.D., Giraud J., Lee Y.H., Shoelson S.E., White M.F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. Journal of Biological Chemistry 2002, 277:1531-1537.
66. Al-Regaiey K.A., Masternak M.M., Bonkowski M., Sun L., Bartke A. Long-lived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor 1/insulin signaling and caloric restriction. Endocrinology 2005, 146:851-860.
67. Westbrook R., Bonkowski M.S., Strader A.D., Bartke A. Alterations in oxygen consumption, respiratory quotient, and heat production in long-lived GHRKO and Ames dwarf mice, and short-lived bGH transgenic mice. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2009, 64:443-451.
68. Masternak M.M., Bartke A., Wang F., et al. Metabolic effects of intra-abdominal fat in GHRKO mice. Aging Cell 2012, 11:73-81.
69. Franceschi C., Olivieri F., Marchegiani F., et al. Genes involved in immune response/inflammation. IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mechanisms of Ageing and Development 2005, 126:351-361.
70. Crimmins E.M., Finch C.E. Infection, inflammation, height, and longevity. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:498-503.
71. Franks A.L., Slansky J.E. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Research 2012, 32:1119-1136.
72. Sluczanowska-Glabowska S., Laszczynska M., Piotrowska K., et al. Morphology of ovaries in laron dwarf mice, with low circulating plasma levels of insulin-like growth factor-1 (IGF-1), and in bovine GH-transgenic mice, with high circulating plasma levels of IGF-1. Journal of Ovarian Research 2012, 5:18.
73. Ratajczak J., Shin D.M., Wan W., et al. Higher number of stem cells in the bone marrow of circulating low Igf-1 level Laron dwarf mice-novel view on Igf-1, stem cells and aging. Leukemia 2011, 25:729-733.
74. Ayuk J., Sheppard M.C. Does acromegaly enhance mortality?. Reviews in Endocrine and Metabolic Disorders 2008, 9:33-39.
75. Ross R., Berentzen T., Bradshaw A.J., et al. Does the relationship between waist circumference, morbidity and mortality depend on measurement protocol for waist circumference?. Obesity Reviews 2008, 9:312-325.
76. Bartke A. Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology 2003, 78:210-216.
77. Roberts R.C. The lifetime growth and reproduction of selected strains of mice. Heredity 1961, 16:369-381.
78. Yuan R., Tsaih S.W., Petkova S.B., et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 2009, 8:277-287.
79. Miller R.A., Harper J.M., Galecki A., Burke D.T. Big mice die young: early life body weight predicts longevity in genetically heterogeneous mice. Aging Cell 2002, 1:22-29.
80. Rollo C.D. Growth negatively impacts the life span of mammals. Evolution and Development 2002, 4:55-61.
81. Patronek G.J., Waters D.J., Glickman L.T. Comparative longevity of pet dogs and humans: implications for gerontology research. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 1997, 52A:B8-B171.
82. Brosnahan M.M., Paradis M.R. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999). Journal of the American Veterinary Medical Association 2003, 223:93-98.
83. Williams G. Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957, 11:398-411.
84. Besson A., Salemi S., Gallati S., et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2003, 88:3664-3667.
85. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine 2011, 3(70):70ra13.
86. Laron Z. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. Hormones (Athens) 2008, 7:24-27.
87. Krzisnik C., Grguric S., Cvijovic K., Laron Z. Longevity of the hypopituitary patients from the island Krk: a follow-up study. Pediatric Endocrinology Reviews 2010, 7:357-362.
88. Aguiar-Oliveira M.H., Oliveira F.T., Pereira R.M., et al. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. Journal of Clinical Endocrinology and Metabolism 2010, 95:714-721.
89. van Heemst D., Beekman M., Mooijaart S.P., et al. Reduced insulin/IGF-1 signaling and human longevity. Aging Cell 2005, 4:79-85.
90. Suh Y., Atzmon G., Cho M.O., et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:3438-3442.
91. Willcox B.J., Donlon T.A., He Q., et al. FOXO3A genotype is strongly associated with human longevity. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:13987-13992.
92. Flachsbart F., Caliebe A., Kleindorp R., et al. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:2700-2705.
93. Pawlikowska L., Hu D., Huntsman S., et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 2009, 8:460-472.
94. Kojima T., Kamei H., Aizu T., et al. Association analysis between longevity in the Japanese population and polymorphic variants of genes involved in insulin and insulin-like growth factor 1 signaling pathways. Experimental Gerontology 2004, 39:1595-1598.
95. Paolisso G., Gambardella A., Ammendola S., et al. Glucose tolerance and insulin action in healthy centenarians. American Journal of Physiology 1996, 270(5 Pt 1):E890-E894.
96. Bonafe M., Barbieri M., Marchegiani F., et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. Journal of Clinical Endocrinology and Metabolism 2003, 88:3299-3304.
97. Bik W., Baranowska-Bik A., Wolinska-Witort E., et al. The relationship between adiponectin levels and metabolic status in centenarian, early elderly, young and obese women. Neuroendocrinology Letters 2006, 27:493-500.
98. Atzmon G., Rincon M., Schechter C.B., et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biology 2006, 4(4):e113.
99. Rozing M.P., Westendorp R.G., de Craen A.J., et al. Favorable glucose tolerance and lower prevalence of metabolic syndrome in offspring without diabetes mellitus of nonagenarian siblings: the Leiden longevity study. Journal of the American Geriatrics Society 2010, 58:564-569.
100. Wijsman C.A., Rozing M.P., Streefland T.C., et al. Familial longevity is marked by enhanced insulin sensitivity. Aging Cell 2011, 10:114-121.
101. Anisimov S.V., Volkova M.V., Lenskaya L.V., Khavinson VKh, Solovieva D.V., Schwartz E.I. Age-associated accumulation of the Apolipoprotein C-III gene T-455C polymorphism C allele in a Russian population. Journal of Gerontology: Biological Sciences 2001, 56A:B27-B32.
102. Barbieri M., Rizzo M.R., Manzella D., et al. Glucose regulation and oxidative stress in healthy centenarians. Experimental Gerontology 2003, 38:137-143.
103. Singal P.K., Beamish R.E., Dhalla N.S. Potential oxidative pathways of catecholamine in the formation of lipid peroxides and genesis of heart disease. Advances in Experimental Medicine and Biology 1983, 161:391-401.
104. Ruiz-Torres A., Soares de Melo Kirzner M. Ageing and longevity are related to growth hormone/insulin-like growth factor-1 secretion. Gerontology 2002, 48:401-407.
105. Roth G.S., Lane M.A., Ingram D.K., et al. Biomarkers of caloric restriction may predict longevity in humans. Science 2002, 297:811.
106. Ulrich P., Cerami A. Protein glycation, diabetes, and aging. Recent Progress in Hormone Research 2001, 6:1-21.
107. Facchini F.S., Hua N.W., Reaven G.M., Stoohs R.A. Hyperinsulinemia, the missing link among oxidative stress and age-related diseases?. Free Radical Biology and Medicine 2000, 29:1302-1306.
108. Facchini F.S., Humphreys M.H., Abbasi F., Donascimento C.A., Reaven G.M. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. American Journal of Clinical Nutrition 2000, 72:776-779.
109. Dilman V.M. Development, aging and disease. A new rationale for an intervention 1994, Harwood Academic Publishers, Chur.
110. Dilman VM Ageing, metabolic immunodepression and carcinogenesis. Mechanisms of Ageing and Development 1978, 8:153-173.
111. Gennigens C., Menetrier-Caux C., Droz J.P. Insulin-Like Growth Factor (IGF) family and prostate cancer. Critical Reviews in Oncology/Hematology 2006, 58:124-145.
112. Pavlidis N., Stanta G., Audisio R.A. Cancer prevalence and mortality in centenarians: a systematic review. Critical Reviews in Oncology/Hematology 2012, 83:145-152.
113. Gupta K., Krishnaswamy G., Karnad A., Peiris A.N. Insulin: a novel factor in carcinogenesis. American Journal of the Medical Sciences 2002, 323:140-145.
114. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results in Cancer Research 2007, 174:49-53.
115. Hadley E.C., Dutta C., Finkelstein J., et al. Human implications of caloric restriction's effect on laboratory animals: an overview of opportunities for research. Journal of Gerontology A 2001, 56A(Special issue I):5-6.
116. Weindruch R., Keenan K.P., Carney J.M., et al. Caloric restriction mimetics, metabolic intervention. Journal of Gerontology Series A: Biological Sciences 2001, 56A(Special Issue 1):20-33.
117. Blagosklonny M.V. Aging and immortality, quasi-programmed senescence and its phamacological inhibition. Cell Cycle 2006, 5:2087-2102.
118. Blagosklonny M.V. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discovery Today 2007, 12:218-224.
119. Longo V.D., Finch C.E. Genetics of aging and diseases: from rare mutations and model systems to disease prevention. Archives of Neurology 2002, 59:1706-1708.
120. Muntoni S. Inhibition of fatty acid oxidation by biguanides, implication for metabolic physiopathology. Advances in Lipid Research 1974, 12:311-377.
121. Muntoni S. Metformin and fatty acids. Diabetes Care 1999, 22:179-180.
122. Dilman V.M., Berstein L.M., Ostroumova M.N., et al. Metabolic immunodepression and metabolic immunotherapy, an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 1982, 39:13-19.
123. Dilman V.M., Berstein L.M., Yevtushenko T.P., et al. Preliminary evidence on metabolic rehabilitation in cancer patients. Archiv fur Geschwulstforschung 1988, 58:175-183.
124. Berstein L.M., Evtushenko T.P., Tsyrlina E.V., et al. Comparative study of 5- and 10-year-long results of the metabolic rehabilitation of cancer patients. Neuroendocrine system, metabolism, immunity and cancer (clinical aspects) 1992, 102-112. NN Petrov Research Institute of Oncology Publ., St. Petersburg. K.P. Hanson, V.M. Dilman (Eds.).
125. Berstein L.M., Kvatchevskaya JuO., Poroshina T.E., et al. Insulin resistance, its consequences for clinical course of the disease and possibilities of correction in endometrial cancer. Journal of Cancer Research and Clinical Oncology 2004, 130:687-693.
126. Berstein L.M. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Letters 2005, 224:203-212.
127. Berstein L.M. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncology 2010, 6:1311-1323.
128. Dilman V.M. Age-associated elevation of hypothalamic threshold to feedback control and its role in development, aging and disease. Lancet 1971, 1:1211-1219.
129. Bakaev V.V. Effect of 1-butylbiguanide hydrochloride on the longevity in the nematoda Caenorhabditis elegans. Biogerontology 2002, 3 Suppl.:23-24.
130. Onken B., Driscoll M. Metformin induces dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN-1. PLoS ONE 2010, 5(1):e8758. 10.1371/journal.pone.0008758.
131. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in metvhaism of metformin action. Journal of Clinical Investigation 2001, 108:1167-1174.
132. Shaw R.J., Lamia K.A., Vasquez D., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
133. Dilman V.M., Anisimov V.N. Effect of treatment with phenfromin, dyphenylhydantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice. Gerontology 1980, 26:241-245.
134. Anisimov V.N., Berstein L.M., Egormin P.A., et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology 2005, 40:685-693.
135. Anisimov V.N., Egormin P.A., Piskunova T.S., et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010, 9:188-197.
136. Anisimov V.N., Berstein L.M., Egormin P.A., et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008, 7:2769-2773.
137. Anisimov V.N., Berstein L.M., Popovich I.G., et al. If started early in life, metformin increases life span and postpones tumors in female SHR mice. Aging (Albany, NY) 2011, 3:148-157.
138. Anisimov V.N., Piskunova T.S., Popovich I.G., et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany, NY) 2010, 2:945-958.
139. Anisimov V.N., Semenchenko A.V., Yashin A.I. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 2003, 4:297-307.
140. Anisimov V.N. Effect of buformin and diphenylhydantoin on life span, estrus function and spontaneous tumor incidence in female rats. Voprosy Onkologii 1980, 6:42-48.
141. Smith D.L., Elam C.F., Mattison J.A., et al. Metformin supplementation and life span in Fischer-344 rats. Journal of Gerontology Series A: Biological Sciences 2010, 65A:468-474.
142. Ma T.C., Buescher J.L., Oatis B., et al. Metformin therapy in a transgenic mouse model of Hungtington's disease. Neuroscience Letters 2007, 411:98-103.
143. Yu B.P. Modulation of aging processes by dietary restriction 1994, CRC Press, Boca Raton, 264 pp.
144. Scarpello J.H. Improving survival with metformin, the evidence base today. Diabetes and Metabolism 2003, 29:6S36-43S.
145. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345-2351.
146. Anisimov V.N., Popovich I.G., Zabezhinski M.A. Methods of evaluating the effect of pharmacological drugs on aging and life span in mice. Methods in Molecular Biology 2007, 371:227-236.
147. Anisimov V.N., Dilman V.M. The increase of hypothalamic sensitivity to the inhibition by estrogens induced by the treatment with L-DOPA, diphenylhydantoin or phenformin in old rats. Bulletin of Experimental Biology and Medicine 1975, 11:96-98.
148. Dilman V.M., Anisimov V.N. Hypothalamic mechanisms of ageing and of specific age pathology-I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Experimental Gerontology 1979, 14:161-174.
149. Rossmanith W.G. Neuroendocrinology of aging in the reproductive system, gonadotropin secretion as an example 2001, Narosa Publ House, New Dehli, p. 15-25.
150. Hung A.J., Stanbury M.G., Shanabrough M., Horvath T.L., Garcia-Segura L.M., Naftolin F. Estrogen, synaptic plasticity and hypothalamic reproductive aging. Experimental Gerontology 2003, 38:53-59.
151. Yaghmaie F., Garan S.A., Massaro M., Timiras P.S. A comparison of estrogen receptor-alpha immunoreactivity in the arcuate hypothalamus of young and middle-aged C57BL6 female mice. Experimental Gerontology 2003, 38:220.
152. Awartani K.A., Cheung A.P. Metformin and polycystic ovary syndrome, a literature review. Journal of Obstetrics and Gynaecology Canada 2002, 24:393-401.
153. Nestler J.E., Stovall D., Akhther N., Iorno M.J., Jakubowicz D.J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility and Sterility 2002, 77:209-215.
154. Fernandes M.L., Saad M.J., Velloso L.A. Effect of age on elements of insulin-signaling pathway in central nervous system of rats. Endocrine 2001, 16:227-234.
155. Richards J.S., Russell D.L., Ochsner S., et al. Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization. Recent Progress in Hormone Research 2002, 57:195-220.
156. Chiba T., Yamaza H., Higami Y., Shimokawa I. Anti-aging effects of caloric restriction. Involvement of neuroendocrine adaptation by peripheral signaling. Microscopy Research and Technique 2002, 59:317-324.
157. Mattson M.P., Duan W., Maswood N. How does the brain control lifespan?. Ageing Research Reviews 2002, 1:155-165.
158. McCarty M.F. Longevity effect of chromium picolinate-'rejuvenation' of hypothalamic function?. Medical Hypotheses 1994, 3:253-265.
159. De Benedictis G., Carotenuto L., Carrieri G., et al. Gene/longevity association studies at four autosomal loci (REN, THO, PARP, SOD2). European Journal of Human Genetics 1998, 6:534-541.
160. De Benedictis G., Tan Q., Jeune B., et al. Recent advances in human gene-longevity association studies. Mechanisms of Ageing and Development 2001, 122:909-920.
161. Huxtable S.J., Saker P.J., Haddad L., et al. Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat allels. Diabetes 2000, 49:126-130.
162. Weaver J.U., Kopelman P.G., Hitman G.A. Central obesity and hyperinsulinemia in women are associated with polymorphism in the 5' flanking region of the human insulin gene. European Journal of Clinical Investigation 1992, 22:265-270.
163. Waterworth D.M., Bennett S.T., Gharani N., et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997, 349:986-990.
164. Tybaierg-Hansen A., Gerdes I.U., Overgaard K., Ingerslev J., Faergeman O., Nerup J. Polymorphism in 5' flanking region of human insulin gene. Relationships with atherosclerosis, lipid levels and age in three samples from Denmark. Arteriosclerosis 1990, 10:372-378.
165. Rennels E.G., Anigstein D.M., Anigstein L. A cumulative study of the growth of sarcoma 180 in anterior pituitary dwarf mice. Texas Reports on Biology and Medicine 1965, 23:776-781.
166. Bielschowsky F., Bielschowsky M. Carcinogenesis in the pituitary dwarf mouse. The response to methylcholanthrene injected subcutaneously. British Journal of Cancer 1959, 13:302-305.
167. Bielschowsky F., Bielschowsky M. Carcinogenesis in the pituitary dwarf mouse. The response to 2-rminofluorene. British Journal of Cancer 1960, 14:195-199.
168. Bielschowsky F., Bielschowsky M. Carcinogenesis in the pituitary dwarf mouse. The response to dimethylbenzanthracene applied to the skin. British Journal of Cancer 1961, 15:257-262.
169. Li S., Crenshaw E.B., Rawson E.J., Simmons D.M., Swanson L.W., Rosenfeld M.G. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990, 347:528-533.
170. Sornson M.W., Wu W., Dasen J.S., et al. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996, 384:327-333.
171. Zhou Y., Xu B.C., Maheshwari H.G., et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proceedings of the National Academy of Sciences of the United States of America 1997, 94:13215-13220.
172. Chen H.W., Meier H., Heiniger H.-J., Huebner R.J. Tumorigenesis in strain DW/J mice and induction by prolactin of the group-specific antigen of endogenous C-type RNA tumor virus. Journal of the National Cancer Institute 1972, 49:1145-1154.
173. Anisimov V.N. Metformin for aging and cancer prevention. Aging (Albany NY) 2010, 2:760-774.
174. Martin-Castillo B., Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Metformin and cancer. Doses, mechanisms and the dandelion and hermetic phenomena. Cell Cycle 2010, 9:1057-1064.
175. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Martin-Castillo B., Menendez J.A. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Current Molecular Medicine 2010, 10:674-691.
176. Dilman V.M., Berstein L.M., Zabezhinski M.A., Alexandrov V.A. On influence of phenformin on induction of mammary tumors in rats. Voprosy Onkologii 1974, 20(9):94-97.
177. Dilman V.M., Berstein L.M., Zabezhinski M.A., Alexandrov V.A., Pliss G.B. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Archiv fur Geschwulstforschung 1978, 48:1-8.
178. Anisimov V.N., Ostroumova M.N., Dilman V.M. Inhibition of blastomogenic effect of 7,12-dimethylbenz(a)-anthracene in female rats by buformin, diphenylhydantoin, polypeptide pineal extract and L-DOPA. Bulletin of Experimental Biology and Medicine 1980, 89:723-725.
179. Anisimov V.N., Belous N.M., Vasilyeva I.A., Dilman V.M. Inhibitory effect of phenformin on the development of mammary tumors induced by N-nitrosomethylurea in rats. Experimental Onkology 1980, 3:40-43.
180. Bojkova B., Orendas P., Garajlova M., et al. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009, 56:269-274.
181. Zhu Z., Jiang W., Thompson M.D., McGinley J., Thompson H.J. Metformin as an energy restriction mimetic agent for breast cancer prevention. Journal of Carcinogenesis 2011, 10:17.
182. Deriabina O.N., Plotnikova N.A., Anisimov V.N. Melatonin and metformin inhibits skin carcinogenesis induced by benzo(a)pyrene in mice. Voprosy Onkologii 2010, 56(6):583-587.
183. Man'cheva T.A., Demidov D.V., Plotnikova N.A., Kharitonova T.V., Paschkevich I.V., Anisimov V.N. Melatonin and metformin inhibit skin carcinogenesis and lipid perooxidation induced by benzo(a)pyrene in female mice. Bulletin of Experimental Biology and Medicine 2011, 151:339-342.
184. Vinnitski V.B., Iakimenko V.A. Effect of phenformin, L-DOPA and para-chlorophenylalanine on the immunological reactivity and chemical carcinogenesis in BALB/c mice. Voprosy Onkologii 1981, 27(6):45-50.
185. Deriabina ON. Inhibitory effect of melatonin and metformin on carcinogenesis induced by benzo(a)pyrene in various tissues of female mice. PhD diss. NN Petrov Res Inst Oncology: St. Petersburg; 2010.
186. Erdemoglu E., Güney M., Giray S.G., Take G., Mungan T. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2009, 145:195-199.
187. Deriabina O.N., Plotnikova N.A., Kharitonova T.V., et al. Melatonin and metformin inhibits development of cervicovaginal tumors induced by benzo(a)pyrene in mice. Morphol Vedomosti 2010, 2:36-41.
188. Memmott R.M., Mercado J.R., Maier C.R., Kawabata S., Fox S.D., Dennis P.A. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prevention Research 2010, 3:1066-1076.
189. Popovich I.G., Pisunova T.S., Tyndyk M.L., Anikin I.V., Zabezhinski M.A., Anisimov V.N. Metformin effect on urethane-induced tumorigenesis in mice. Voprosy Onkologii 2012, 58:549-553.
190. Bhalla K., Hwang B.J., Dewi R.E., et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prevention Research (Phila) 2012, 5:544-552.
191. Schneider M.B., Matsuzaki H., Harorah J., et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120:1263-1270.
192. Hou M., Venier N., Sugar L., et al. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochemical and Biophysical Research Communications 2010, 397:537-542.
193. Vitale-Cross L., Molinolo A.A., Martin D., et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prevention Research 2012, 5:562-573.
194. Huang X., Wullschleger S., Shpiro N., et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochemistry 2008, 412:211-221.
195. Min/+ mice. Cancer Science 2008, 99:2136-2141.
196. Hosono K., Endo H., Takahashi H., et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by AMP-activating protein kinase. Molecular Carcinogenesis 2010, 49:662-671.
197. Shimomoto T., Luo Y., Ohmori H., et al. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. Journal of Gastroenterology 2012, 47:1073-1083.
198. Dilman V.M., Sofronov B.N., Anisimov V.N., Nazarov P.G., L'vovich EG Phenformin elimination of the immunodepression caused by 1,2-dimethylhydrazine in rats. Voprosy Onkologii 1977, 23(8):50-54.
199. Anisimov V.N., Pozharisski K.M., Dilman V.M. Effect of phenformin on the blastomogenic action of 1,2-dimethylhydrazine in rats. Voprosy Onkologii 1980, 26(8):54-58.
200. Bespalov V.G., Alexandrov V.A. Influence of anticarcinogenic agents on the transplacental carcinogenic effect of N-nitroso-N-ethylurea. Bulletin of Experimental Biology and Medicine 1985, 100:73-76.
201. Alexandrov V.A., Anisimov V.N., Belous N.M., Vasilyeva I.A., Mazon V.B. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats. Carcinogenesis 1980, 1:975-978.
202. Anisimov V.N., Belous N.M., Prokudina E.A. Inhibition by phenformin of the radiation carcinogenesis in female rats. Experimental Onkology 1982, 4(6):26-29.
203. Wu Y., Yakar S., Zhao L., Hennighausen L., LeRoith D. Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis. Cancer Research 2002, 62:1030-1035.
204. Saydah S.H., Loria C.M., Eberhardt M.S., Brancati F.L. Abnormal glucose tolerance and the risk of cancer death in the United States. American Journal of Epidemiology 2003, 157:1092-1100.
205. Lipscombe L.L., Goodwin P.J., Zinman B., McLaughlin J.R., Hux J.E. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Research and Treatment 2006, 98:349-356.
206. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. British Medical Journal 2005, 330:1304-1305.
207. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylurea or insulin. Diabetes Care 2006, 29:254-258.
208. Costello M., Shrestha B., Eden J., Sjoblom P., Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2007, 1(January):CD005552.
209. Beckman R. Biguanide (Experimental Teil). Handbook of experimental pharmacology 1971, vol. 29:439-596. Springer-Verlag, Berlin.
210. Wysocki P.J., Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Review of Molecular Diagnostics 2010, 10:509-519.
211. Kiho T., Kato M., Usui S., Hirano K. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clinica Chimica Acta 2005, 358:139-145.
212. Diamanti-Kandarakis E., Alexandraki K., Piperi C., et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental 2007, 6:129-134.
213. Nedosugova L.V., Lankin V.Z., Reznik S.M., et al. Effect of metformin on oxidative stress rate in type 2 diabetic patients. Probl Endocrinol 2007, 53:3-7.
214. El-Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. Journal of Biological Chemistry 2000, 275:223-228.
215. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts it anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal 2000, 348:607-614.
216. Brunmair B., Staniek K., Gras F., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53:1052-1059.
217. Aleisa A.M., Al-Rejaie S.S., Bakheer S.A., et al. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice. Mutation Research 2007, 634:93-100.
218. Holland W., Morrison T., Chang Y., Wiernsperger N., Stith B.J. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochemical Pharmacology 2004, 67:2081-2091.
219. Fulgencio J.P., Kohl C., Girard J., Pégorier J.P. Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochemical Pharmacology 2001, 62:439-446.
220. Heishi M., Ichihara J., Teramoto R., et al. Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia 2006, 49:1647-1655.
221. Kalender A., Selvaraj A., Kim S.Y., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metabolism 2010, 11:390-401.
222. Spindler S.R. Use of microarray biomarkers to identify longevity therapeutics. Aging Cell 2006, 5:39-50.
223. Dhahbi J.M., Mote P.L., Fahy G.M., Spindler S.R. Identification of potential caloric restriction mimetics by microarray profiling. Physiological Genomics 2005, 23:343-350.
224. Gargiulo P., Caccese D., Pignatelli P., et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes/Metabolism Research and Reviews 2002, 8:156-159.
225. Popovich I.G., Zabezhinski M.A., Egormin P.A., et al. Insulin in aging and cancer: new antidiabetic drug Diabenol as geroprotector and anticarcinogen. International Journal of Biochemistry and Cell Biology 2005, 37:1117-1129.
226. Solano M.E., Sander V., Wald M.R., Motta A.B. Dehydroepiandrosetrone and metformin regulate proliferation of murine T-lymphocytes. Clinical and Experimental Immunology 2008, 153:289-296.
227. Morales A.I., Detaille D., Prieto M., et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney International 2010, 77:861-869.
228. Zorov D.B. Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria. Kidney International 2010, 77:841-843.
229. Attia S.M., Helal G.K., Alhaider A.A. Assessment of genomic instability in normal and diabetic rats treated with metformin. Chemico-Biological Interactions 2009, 180:296-304.
230. Diamanti-Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effect of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. European Journal of Endocrinology 1998, 138:269-274.
231. Liao C.Y., Rikke B.A., Johnson T.E., Diaz V., Nelson J.F. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell 2010, 9:92-95.
232. Taubes G. Cancer prevention with a diabetes pill?. Science 2012, 335:29.
233. Zakikhani M., Dowling R., Fantus I.G., et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 2006, 66:10269-10273.
234. Alimova I.N., Liu B., Fan Z., et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 15:909-915.
235. Liu H., Scholz C., Zang C., et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Research 2012, 32:1627-1637.
236. Goodwin P.A. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?. Journal of Clinical Oncology 2008, 26:833-834.